Structure Therapeutics (NASDAQ:GPCR) Earns Buy Rating from Analysts at Stifel Nicolaus

Research analysts at Stifel Nicolaus began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a report released on Wednesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $50.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 83.96% from the company’s current price.

A number of other analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities restated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Morgan Stanley began coverage on Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Price Performance

Structure Therapeutics stock opened at $27.18 on Wednesday. Structure Therapeutics has a 12-month low of $25.90 and a 12-month high of $62.74. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -36.73 and a beta of -2.78. The firm’s fifty day moving average price is $32.85 and its 200 day moving average price is $36.77.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Sandia Investment Management LP bought a new stake in Structure Therapeutics during the second quarter valued at $39,000. GAMMA Investing LLC grew its position in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares during the last quarter. Assetmark Inc. raised its stake in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after acquiring an additional 719 shares during the period. Quarry LP acquired a new stake in Structure Therapeutics during the second quarter worth about $79,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after acquiring an additional 1,420 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.